Design, synthesis, evaluation and 3D-QSAR analysis of benzosulfonamide benzenesulfonates as potent and selective inhibitors of MMP-2

被引:11
作者
Qiu, Han-Yue [1 ]
Wang, Zhong-Chang [1 ]
Wang, Peng-Fei [1 ]
Yan, Xiao-Qiang [1 ]
Wang, Xiao-Ming [1 ]
Yang, Yong-Hua [1 ]
Zhu, Hai-Liang [1 ]
机构
[1] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China
关键词
MATRIX-METALLOPROTEINASE INHIBITORS; CANCER; PROLIFERATION; THERAPY; S-1';
D O I
10.1039/c4ra06438k
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A novel series of MMPIs was designed, synthesized and purified using a scaffold modification strategy. The new compounds were also evaluated for biological activity against A549, MCF-7, HepG2 and Hela as potential inhibitors of MMP-2. The most potent inhibitor against MMP-2 was compound 19 (IC50 = 0.38 mu M). Its antitumor effect is believed to be due to the induction of apoptosis, which is further confirmed by Annexin V-FITC/PI staining assay using flow cytometry analysis. Furthermore, all the compounds were evaluated for cytotoxicity against 293T. In addition, 3D-QSAR studies were conducted. The result showed that the benzosulfonamide benzenesulfonate MMPIs may prove interesting lead candidates to target MMP-2 associated tumor, where the MMP-2 domain is located extracellularly.
引用
收藏
页码:39214 / 39225
页数:12
相关论文
共 38 条
[1]   Matrix metalloproteinase inhibitors 1998 [J].
Beckett, RP ;
Whittaker, M .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (03) :259-282
[2]   Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer [J].
Bissett, D ;
O'Byrne, KJ ;
von Pawel, J ;
Gatzemeier, U ;
Price, A ;
Nicolson, M ;
Mercier, R ;
Mazabel, E ;
Penning, C ;
Zhang, MH ;
Collier, MA ;
Shepherd, FA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :842-849
[3]   ZP4, an improved neuronal Zn2+ sensor of the Zinpyr family [J].
Burdette, SC ;
Frederickson, CJ ;
Bu, WM ;
Lippard, SJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (07) :1778-1787
[4]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[5]  
Dhanaraj V, 1999, CROAT CHEM ACTA, V72, P575
[6]   Matrix metalloproteinases as valid clinical targets [J].
Fingleton, Barbara .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (03) :333-346
[7]   Specific targeting of metzincin family members with small-molecule inhibitors: Progress toward a multifarious challenge [J].
Georgiadis, Dimitris ;
Yiotakis, Athanasios .
BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (19) :8781-8794
[8]   N-aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases:: further probing of the S1, S1′, and S2′ pockets [J].
Hanessian, S ;
Moitessier, N ;
Gauchet, C ;
Viau, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (19) :3066-3073
[9]   Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade™ in patients with rheumatoid arthritis [J].
Hemmings, FJ ;
Farhan, M ;
Rowland, J ;
Banken, L ;
Jain, R .
RHEUMATOLOGY, 2001, 40 (05) :537-543
[10]   Development of matrix metalloproteinase inhibitors in cancer therapy [J].
Hidalgo, M ;
Eckhardt, SG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (03) :178-193